Authors who work with cameras need to know cons and pros of some…
Prince Giri
The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a list of…
Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics possessing similar therapeutic properties in terms of potency- safety- and efficacy to original biologic products. The companies are focusing…
Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology- neuroscience- oncology- rare diseases- and plasma-derived therapies. This article is based on the 2018…
The global generics pharmaceutical market is continuously growing and increasing with its accessibility & benefits offered as efficient and economical drugs- are always needed in the market. Generics are approved copies of small molecule drugs which contain the same amount of active ingredients- dosage form- safety- strength- route of administration- quality- performance characteristics- as of…
Healthcare- pharmaceutical- and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in 2018. The highest valued deal proved to be of Takeda's acquisition of Shire for $57B with the focus on global R&D- its robust and modality-diverse…
The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology- Hematology and multiple diseases but due to a drastic increase in the immune disorders- Immunology segment has been widely spared across the globe. In the top 20…
With the era of growing diseases- Diagnostics have played a vital role in diagnosing multiple diseases and disorders. The healthcare system is changing- with a greater focus on value- reducing errors and giving more cost-effective care and treatments. The Diagnostic ledger has not changed much in comparison to 2017. Roche Diagnostics holds to be at…
The Medical device market is growing with greater needs of patients and with their emerging diseases. 2018 has shown major advancement in medical device needs and upgrades with 55 novel drug approvals. The year 2018 has shown a slight change in the ledger of top 20 firms while Medtronic holds its first position with a…
The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced- effective- and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top…